LISTEN: The FDA’s cold shoulder, the latest CAR-T contender, and how Grindr relates to personal genetics

What’s it like to be a biotech investor? Do you know where your genetic data are? And what does it mean when the FDA swipes left on your drug?

We tackle all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a recap of the lively chat about capitalism we had on Wednesday, a dive into the latest CAR-T upheaval, and a discussion of how the FDA’s quote-unquote flexibility might be a little more rigid than biotech thought. Also we talk about Grindr.

For more on the topics we cover, here’s a story on the new CAR-T company; here’s the news on Alkermes and the FDA; and here’s the BuzzFeed News scoop on Grindr.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].